Cadrenal Therapeutics Inc — Cash Flow (NASDAQ:CVKD)

Financials

Cash from operating activities -60-3.53 M-7.36 M-12.6 M -12.6 M Cash from investing activities —-3 254-6 537-5 104 -5 104 Cash from financing activities —11.9 M8.98 M6.6 M 6.6 M Free cash flow -60-3.53 M-7.36 M-12.61 M -12.61 M

News

Cadrenal schedules FDA meeting for HIT drug CAD-1005

Cadrenal Therapeutics stock surges on Phase 2 trial results

Cadrenal’s CAD-1005 shows reduction in blood clots in HIT trial

Cadrenal highlights potential of 12-LOX inhibitor for blood disorder

Cadrenal Therapeutics acquires first-in-class HIT treatment from Veralox

Cadrenal Therapeutics appoints PTC Therapeutics CMO to board

Cadrenal Therapeutics, Inc.

Cadrenal therapeutics CFO Szot sells $1496 in shares

Szot, CFO of Cadrenal, sells $174k in CVKD stock

Cadrenal therapeutics (CVKD) CEO Pham sells $131,779 in stock

Cadrenal Therapeutics acquires eXIthera’s anticoagulant portfolio